| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tuğba Kontbay, Zeynep Şıklar, Elif Özsu, Rukiye Uyanık, Esra Bilici, Ayşegül Ceran, Merih Berberoğl. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience. The Turkish journal of pediatrics. vol 64. issue 5. 2022-10-28. PMID:36305439. |
dopamine agonists are the first step in the treatment of prolactinomas. |
2022-10-28 |
2023-08-14 |
Not clear |
| Bahar K Force, Kristen Staggers, Sherly Sebastian, Mas Takashima, Daniel Yoshor, Susan L Samso. ENDOSCOPIC ENDONASAL TRANSSPHENOIDAL SURGERY FOR PATIENTS WITH PROLACTINOMAS: Indications and Outcomes. World neurosurgery. 2022-10-21. PMID:36270592. |
clinical paradigms and consensus recommend dopamine agonists (da) as the primary treatment for prolactinomas. |
2022-10-21 |
2023-08-14 |
Not clear |
| Adam Mamela. Surgery as a first-line option for prolactinomas. Expert review of endocrinology & metabolism. 2022-10-06. PMID:36200144. |
treatment of prolactinomas with dopamine agonists has been the established first-line treatment option for many years, with surgery reserved for refractory cases or medication intolerance. |
2022-10-06 |
2023-08-14 |
Not clear |
| Anahid Hamidianjahromi, Nicholas A Trito. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Reviews in endocrine & metabolic disorders. 2022-09-20. PMID:36125673. |
dopamine agonists (das) represent a mainstay of therapy for hyperprolactinemia and prolactinomas. |
2022-09-20 |
2023-08-14 |
Not clear |
| Daniele Nucci, Omar Enzo Santangelo, Sandro Provenzano, Mariateresa Nardi, Alberto Firenze, Vincenza Gianfred. Altered Food Behavior and Cancer: A Systematic Review of the Literature. International journal of environmental research and public health. vol 19. issue 16. 2022-08-26. PMID:36011935. |
food craving has been associated with different types of cancer in adults and young patients, as well as with orthorexia; conversely, compulsive eating has only been explored in patients with prolactinoma treated with dopamine agonists. |
2022-08-26 |
2023-08-14 |
human |
| Warrick J Inder, Christina Jan. Treatment of Prolactinoma. Medicina (Kaunas, Lithuania). vol 58. issue 8. 2022-08-26. PMID:36013562. |
dopamine agonists (das) have traditionally been the primary treatment for the majority of prolactinomas, with surgery considered the second line. |
2022-08-26 |
2023-08-14 |
Not clear |
| Noriaki Fukuhara, Mitsuru Nishiyama, Yasumasa Iwasak. Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma. Cancers. vol 14. issue 15. 2022-07-27. PMID:35892862. |
for treating prolactinoma, dopamine agonists (das) are effective for decreasing prl levels and shrinking tumor size in most patients. |
2022-07-27 |
2023-08-14 |
Not clear |
| Juan Chen, Xiang Guo, Zhuangzhuang Miao, Zhuo Zhang, Shengwen Liu, Xueyan Wan, Kai Shu, Yan Yang, Ting Le. Extra-Pseudocapsular Transsphenoidal Surgery for Microprolactinoma in Women. Journal of clinical medicine. vol 11. issue 13. 2022-07-09. PMID:35807204. |
a recall for histological pseudocapsule (ps) and reappraisal of transsphenoidal surgery (tss) as a viable alternative to dopamine agonists in the treatment algorithm of prolactinomas are getting vibrant. |
2022-07-09 |
2023-08-14 |
Not clear |
| Hanna Szmygin, Joanna Szydełko, Beata Matyjaszek-Matusze. Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review. Journal of clinical medicine. vol 11. issue 11. 2022-06-10. PMID:35683457. |
prolactinomas are preferentially treated with dopamine agonists and respond to such therapy with hormonal normalisation and tumour shrinkage. |
2022-06-10 |
2023-08-14 |
Not clear |
| Hanna Szmygin, Joanna Szydełko, Beata Matyjaszek-Matusze. Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review. Journal of clinical medicine. vol 11. issue 11. 2022-06-10. PMID:35683457. |
however, about 10-20% of prolactinomas are resistant to dopamine agonists. |
2022-06-10 |
2023-08-14 |
Not clear |
| Hanna Szmygin, Joanna Szydełko, Beata Matyjaszek-Matusze. Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review. Journal of clinical medicine. vol 11. issue 11. 2022-06-10. PMID:35683457. |
the management of dopamine agonist-resistant prolactinomas poses a therapeutic challenge and includes several possible approaches. |
2022-06-10 |
2023-08-14 |
Not clear |
| Nourah Almutlaq, Erica A Eugster, Zeina Nabhan, Diane Donega. Outcome of Dopamine Agonist Therapy Withdrawal in Children with Prolactinomas. Hormone research in paediatrics. 2022-05-24. PMID:35609555. |
outcome of dopamine agonist therapy withdrawal in children with prolactinomas. |
2022-05-24 |
2023-08-13 |
Not clear |
| Sedat Ava, Leyla Hazar, Mine Karahan, Seyfettin Erdem, Mehmet Emin Dursun, Zafer Pekkolay, Uğur Keklikç. Quantitative Evaluation of Pupil Responses in Patients with Prolactinomas Being Treated with Dopamine Agonists. Neuro-ophthalmology (Aeolus Press). vol 46. issue 3. 2022-05-16. PMID:35574168. |
quantitative evaluation of pupil responses in patients with prolactinomas being treated with dopamine agonists. |
2022-05-16 |
2023-08-13 |
Not clear |
| Sedat Ava, Leyla Hazar, Mine Karahan, Seyfettin Erdem, Mehmet Emin Dursun, Zafer Pekkolay, Uğur Keklikç. Quantitative Evaluation of Pupil Responses in Patients with Prolactinomas Being Treated with Dopamine Agonists. Neuro-ophthalmology (Aeolus Press). vol 46. issue 3. 2022-05-16. PMID:35574168. |
the aim of this study was to determine whether the dopamine agonist (da) drug cabergoline used in the treatment of prolactinoma causes autonomic dysfunction by measuring static and dynamic pupillary responses. |
2022-05-16 |
2023-08-13 |
Not clear |
| Marisa Khatijah Borhan, Florence Hui Sieng Ta. Aggressive giant prolactinoma: a case report. Journal of medical case reports. vol 16. issue 1. 2022-04-30. PMID:35488355. |
managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited. |
2022-04-30 |
2023-08-13 |
Not clear |
| Xiangming Cai, Junhao Zhu, Jin Yang, Chao Tang, Zixiang Cong, Chiyuan M. Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. Chinese neurosurgical journal. vol 8. issue 1. 2022-04-09. PMID:35395837. |
are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? |
2022-04-09 |
2023-08-13 |
Not clear |
| Xiangming Cai, Junhao Zhu, Jin Yang, Chao Tang, Zixiang Cong, Chiyuan M. Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis. Chinese neurosurgical journal. vol 8. issue 1. 2022-04-09. PMID:35395837. |
for prolactinoma patients, dopamine agonists (das) are indicated as the first-line treatment and surgery is an adjunctive choice. |
2022-04-09 |
2023-08-13 |
Not clear |
| C Capatina, C Poian. Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas. Acta endocrinologica (Bucharest, Romania : 2005). vol 17. issue 3. 2022-03-28. PMID:35342478. |
medical treatment with dopamine agonists (da) is the mainstay in the management of prolactinomas. |
2022-03-28 |
2023-08-13 |
Not clear |
| Milagros Peña-Zanoni, Erika Yanil Faraoni, Alejandra Inés Abeledo Machado, Pablo Aníbal Pérez, Carla Agustina Marcial, María Andrea Camilletti, Silvina Gutiérrez, Susana B Rulli, Graciela Diaz-Torg. Oophorectomy improves pituitary activin inhibitory function preventing lactotroph hyperplasia. Endocrine-related cancer. 2022-03-24. PMID:35324456. |
dopamine agonists are generally effective in the treatment of prolactinomas. |
2022-03-24 |
2023-08-13 |
mouse |
| Sameah A Haider, Shiri Levy, Jack P Rock, John R Crai. Prolactinoma: Medical and Surgical Considerations. Otolaryngologic clinics of North America. 2022-03-08. PMID:35256169. |
although the mainstay of prolactinoma management is medical therapy with dopamine agonists, endoscopic endonasal or transcranial surgery, radiation therapy, or a combination of these is an important treatment option in select cases. |
2022-03-08 |
2023-08-13 |
Not clear |